Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

143.18
+2.471.76%
Post-market: 142.40-0.7800-0.54%19:30 EDT
Volume:1.65M
Turnover:235.71M
Market Cap:14.60B
PE:20.98
High:144.56
Open:141.41
Low:140.36
Close:140.71
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.03
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.95
PE(LYR):30.66

Loading ...

Unicycive Therapeutics Appoints Meredith Manning to Board, Names Her Nominating Committee Chair

Reuters
·
Oct 01

Neurocrine Launches PWS-VISTA Real-World Study Tracking VYKAT XR Use in Prader-Willi Syndrome

Reuters
·
Sep 30

Neurocrine is Maintained at Buy by UBS

Dow Jones
·
Sep 30

Neurocrine (NBIX) Receives a Buy from Jefferies

TIPRANKS
·
Sep 29

Neurocrine Biosciences Names Eiry W. Roberts Chief Medical Officer, Replacing Sanjay Keswani

Reuters
·
Sep 29

Neurocrine Biosciences Appoints Eiry W. Roberts, M.d., as Chief Medical Officer

THOMSON REUTERS
·
Sep 29

Bernstein Remains a Buy on Neurocrine (NBIX)

TIPRANKS
·
Sep 26

Neurocrine (NBIX) Gets a Buy from RBC Capital

TIPRANKS
·
Sep 24

Neurocrine (NBIX) Receives a Buy from CCB Intl.

TIPRANKS
·
Sep 21

RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating

MT Newswires Live
·
Sep 21

Neurocrine Biosciences, Inc. : RBC Cuts Target Price to $187 from $198

THOMSON REUTERS
·
Sep 21

US Research Roundup-eBay, Sunbelt Rentals, T-Mobile

Reuters
·
Sep 21

Neurocrine (NBIX) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 15

Neurocrine is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Sep 12

Neurocrine Biosciences Inc : Morgan Stanley Raises Target Price to $183.00 from $182.00

THOMSON REUTERS
·
Sep 11

Neurocrine Chief Commercial Officer Eric Benevich Disposes of 2,154 Common Shares Worth $333,428.94

Reuters
·
Sep 11

Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Neurocrine Price Target Raised to $253.00/Share from $249.00 by Citigroup

Dow Jones
·
Sep 04

Neurocrine price target raised to $253 from $249 at Citi

TIPRANKS
·
Sep 03